Therapeutic effect of Yunnan Baiyao on rheumatoid arthritis was partially due to regulating arachidonic acid metabolism in osteoblasts

Journal of Pharmaceutical and Biomedical Analysis

Volumn 59, Issue 1, 2012, Pages 130-137

  He, Hongbing ^a,b   Ren, Xiaobin ^b   Wang, Xiyue ^a   Shi, Xianzhe ^a   Wang, Xiaolin ^a   Ding, Zhongjuan ^b   Gao, Peng ^a   Xu, Guowang ^a  

^a DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^b KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Arachidonic acid; Metabonomics; Osteoblast; Rheumatoid arthritis; Traditional Chinese Medicine

Indexed keywords

ARACHIDONIC ACID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DRUG METABOLITE; METHOTREXATE; PROSTAGLANDIN D2; PROSTAGLANDIN E2; THROMBOXANE B2; UNCLASSIFIED DRUG; YUNNAN BAIYAO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARACHIDONIC ACID METABOLISM; ARTICLE; CHINESE MEDICINE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; RHEUMATOID ARTHRITIS; URINALYSIS;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONIC ACID; ARTHRITIS, RHEUMATOID; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUGS, CHINESE HERBAL; HUMANS; MALE; OSTEOBLASTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 82255179021     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.10.019     Document Type: Article

References (28)

1. Mayoux-Benhamou M.A. Fatigue and rheumatoid arthritis. Ann. Readapt. Med. Phys. 2006, 49:301-308.
2. Criswell L.A. Gene discovery in rheumatoid arthritis highlights the CD40/NF-kappaB signaling pathway in disease pathogenesis. Immunol. Rev. 2010, 233:55-61.
3. Tobon G.J., Youinou P., Saraux A. The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. J. Autoimmun. 2010, 35:10-14.
4. Kooloos W.M., Huizinga T.W., Guchelaar H.J., Wessels J.A. Pharmacogenetics in treatment of rheumatoid arthritis. Curr. Pharm. Des. 2010, 16:164-175.
5. Dale J., Alcorn N., Capell H., Madhok R. Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs. Nat. Clin. Pract. Rheumatol. 2007, 3:450-458.
6. Zhang P., Li J., Han Y., Yu X.W., Qin L. Traditional Chinese medicine in the treatment of rheumatoid arthritis: a general review. Rheumatol. Int. 2010, 30:713-718.
7. Goldring S.R., Gravallese E.M. Mechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications. Arthritis Res. 2000, 2:33-37.
8. Nicholson J.K., Wilson I.D., Lindon J.C. Pharmacometabonomics as an effector for personalized medicine. Pharmacogenomics 2011, 12:103-111.
9. van W.H., Yuan K., Lu C., Gao P., Wang J., Xiao C., Yan X., Wang M., Schroen J., Lu A., Xu G., van der Greef J. Systems biology guided by Chinese medicine reveals new markers for sub-typing rheumatoid arthritis patients. J. Clin. Rheumatol. 2009, 15:330-337.
10. Xiang Z., Wang X.Q., Cai X.J., Zeng S. Metabolomics study on quality control and discrimination of three curcuma species based on gas chromatograph-mass spectrometry. Phytochem. Anal. 2011, 10.1002/pca.1296.
11. Qiu Y., Chen M., Su M., Xie G., Li X., Zhou M., Zhao A., Jiang J., Jia W. Metabolic profiling reveals therapeutic effects of Herba Cistanches in an animal model of hydrocortisone-induced 'kidney-deficiency syndrome'. Chin. Med. 2008, 3:3-10.
12. Nishikawa M., Myoui A., Tomita T., Takahi K., Nampei A., Yoshikawa H. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum. 2003, 48:2670-2681.
13. Chen Q., Wei W. Effects and mechanisms of glucosides of chaenomeles speciosa on collagen-induced arthritis in rats. Int. Immunopharmacol. 2003, 3:593-608.
14. Strand V., Scott D.L., Emery P., Kalden J.R., Smolen J.S., Cannon G.W., Tugwell P., Crawford B. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J. Rheumatol. 2005, 32:590-601.
15. Yin P., Mohemaiti P., Chen J., Zhao X., Lu X., Yimiti A., Upur H., Xu G. Serum metabolic profiling of abnormal savda by liquid chromatography/mass spectrometry. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2008, 871:322-327.
16. Wu Z., Li M., Zhao C., Zhou J., Chang Y., Li X., Gao P., Lu X., Li Y., Xu G. Urinary metabonomics study in a rat model in response to protein-energy malnutrition by using gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry. Mol. Biosyst. 2010, 6:2157-2163.
17. Dietmair S., Timmins N.E., Gray P.P., Nielsen L.K., Kromer J.O. Towards quantitative metabolomics of mammalian cells: development of a metabolite extraction protocol. Anal. Biochem. 2010, 404:155-164.
18. Yin P., Zhao X., Li Q., Wang J., Li J., Xu G. Metabonomics study of intestinal fistulas based on ultraperformance liquid chromatography coupled with Q-TOF mass spectrometry (UPLC/Q-TOF MS). J. Proteome Res. 2006, 5:2135-2143.
19. Bijlsma S., Bobeldijk I., Verheij E.R., Ramaker R., Kochhar S., Macdonald I.A., van Ommen B., Smilde A.K. Large-scale human metabolomics studies: a strategy for data (pre-)processing and validation. Anal. Chem. 2006, 78:567-574.
20. Yin P., Wan D., Zhao C., Chen J., Zhao X., Wang W., Lu X., Yang S., Gu J., Xu G. A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry. Mol. Biosyst. 2009, 5:868-876.
21. Zhang F., Jia Z., Gao P., Kong H., Li X., Chen J., Yang Q., Yin P., Wang J., Lu X., Li F., Wu Y., Xu G. Metabonomics study of atherosclerosis rats by ultra fast liquid chromatography coupled with ion trap-time of flight mass spectrometry. Talanta 2009, 79:836-844.
22. Fraser D.A., Thoen J., Rustan A.C., Forre O., Kjeldsen-Kragh J. Changes in plasma free fatty acid concentrations in rheumatoid arthritis patients during fasting and their effects upon T-lymphocyte proliferation. Rheumatology (Oxford) 1999, 38:948-952.
23. Kaji H., Sugimoto T., Kanatani M., Fukase M., Kumegawa M., Chihara K. Prostaglandin E2 stimulates osteoclast-like cell formation and bone-resorbing activity via osteoblasts: role of cAMP-dependent protein kinase. J. Bone Miner. Res. 1996, 11:62-71.
24. Park Y.G., Kang S.K., Noh S.H., Park K.K., Chang Y.C., Lee Y.C., Kim C.H. PGE2 induces IL-1beta gene expression in mouse osteoblasts through a cAMP-PKA signaling pathway. Int. Immunopharmacol. 2004, 4:779-789.
25. Mello S.B., Barros D.M., Silva A.S., Laurindo I.M., Novaes G.S. Methotrexate as a preferential cyclooxygenase 2 inhibitor in whole blood of patients with rheumatoid arthritis. Rheumatology (Oxford) 2000, 39:533-536.
26. Dinarello C.A., Cannon J.G., Wolff S.M., Bernheim H.A., Beutler B., Cerami A., Figari I.S., Palladino M.A., O'Connor J.V. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J. Exp. Med. 1986, 163:1433-1450.
27. Yoshida M., Kanno Y., Ishisaki A., Tokuda H., Hirade K., Nakajima K., Katagiri Y., Shimizu K., Kozawa O. Methotrexate suppresses inflammatory agonist induced interleukin 6 synthesis in osteoblasts. J. Rheumatol. 2005, 32:787-795.
28. Yoshida M., Niwa M., Ishisaki A., Hirade K., Ito H., Shimizu K., Kato K., Kozawa O. Methotrexate enhances prostaglandin D2-stimulated heat shock protein 27 induction in osteoblasts. Prostaglandins Leukot. Essent. Fatty Acids 2004, 71:351-362.